A Phase 2 interventional study of VX-371 and Hypertonic Saline in Primary Ciliary Dyskinesia, sponsored by Parion Sciences. Completed at 34 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-12-16.
Sponsored by Parion Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.
Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is one of 2 that started in 2016, is the only one in phase 2, and was the 10th registered.
79 studies on the registry are indexed under Ciliary Motility Disorders; 26 are open to participants now.
Browse Ciliary Motility Disorders studies →9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 8–70 · Healthy volunteers
Connecticut Children's Medical Center · Sites in United States
Ages 2+
Indiana University · Sites in United States
Ages 6+ · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 2–99
The University of Texas Health Science Center, Houston · Sites in United States
Ages 4–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Ciliary Motility Disorders studies recruiting now, 14 (70%) set no upper age limit and 3 (15%) stop at 75 or younger; 17 take children under 18; 7 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 32 across 24 interventional studies indexed under Ciliary Motility Disorders.
Median enrollment 27 across the 9 interventional studies, 150 across the 19 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 28 have an industry lead sponsor. The 10 most frequent:
Parion Sciences is the lead sponsor of 9 studies on the registry; none are open to participants now.
Parion Sciences has 1 study filed under Ciliary Motility Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Ciliary Motility Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03256773University of Alabama at BirminghamHigh Resolution Micro OCT Imaging | 2026-12-31 |
| NCT07699302University of North Carolina, Chapel HillClearance in Primary Ciliary Dyskinesia | 2027-01 |
| NCT00807482University of North Carolina, Chapel HillPathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Ciliary Motility Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional Exclusion Criteria for Part B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
Drug: Hypertonic Saline · Drug: VX-371 + HS
Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
Drug: Hypertonic Saline · Drug: VX-371 + HS
Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
Drug: VX-371 · Drug: Placebo (0.17% saline)
Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
Drug: VX-371 · Drug: Placebo (0.17% saline)
Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
Drug: VX-371 + HS · Drug: Ivacaftor
Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
Drug: Hypertonic Saline · Drug: Ivacaftor
Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
Drug: VX-371 · Drug: Ivacaftor
Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
Drug: Placebo (0.17% saline) · Drug: Ivacaftor
Drug page: Idrevloride
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 84 days that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.
Time frame: Part A: From first dose of study drug up 84 days
Part B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.
Time frame: Part B: Day 85 up to 28 days after last dose of study drug (56 days)
Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
Time frame: Part A: Study Baseline, Day 29 of each treatment period
Part B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
Time frame: Study Baseline, Day 29 of Part B
Part B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
Time frame: Part B Baseline, Day 29 of Part B
Part A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
Time frame: Study Baseline, Day 29 of Part A
Part B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
Time frame: Study Baseline, Day 29 of Part B
Part B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from Part B baseline \>0 indicated improvement. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
Time frame: Part B Baseline, Day 29 of Part B
Part A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29
SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
Time frame: Study Baseline, Day 29 of Part A
Part B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29
SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
Time frame: Study Baseline, Day 29 of Part B
Part B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29
SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
Time frame: Part B Baseline, Day 29 of Part B
| Milestone | Part A: VX-371 in Hypertonic Saline (HS), Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|---|---|---|---|
| Started | 43 | 41 | 21 | 18 | 0 | 0 | 0 | 0 |
| Safety analysis set | 44 | 40 | 21 | 18 | 0 | 0 | 0 | 0 |
| Completed | 40 | 37 | 18 | 16 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 3 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent (not due to adverse event) | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Noncompliant with study drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other withdrawal criteria met | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Wrong drug shipment | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: VX-371 in Hypertonic Saline (HS), Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|---|---|---|---|
| Started | 40 | 37 | 18 | 16 | 0 | 0 | 0 | 0 |
| Safety analysis set | 40 | 37 | 18 | 16 | 0 | 0 | 0 | 0 |
| Completed | 37 | 35 | 17 | 15 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliant with study drug | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: VX-371 in Hypertonic Saline (HS), Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 11 | 27 | 7 | 12 |
| Safety analysis set | 0 | 0 | 0 | 0 | 11 | 27 | 7 | 12 |
| Completed | 0 | 0 | 0 | 0 | 10 | 26 | 6 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 84 days that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.
| Participants | Part A: VX-371 in HS | Part A: HS | Part A: VX-371 | Part A: Placebo |
|---|---|---|---|---|
| Participants with TEAEs | 52 | 46 | 22 | 23 |
| Participants with Serious TEAEs | 1 | 1 | 1 | 1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both serious and non-serious TEAEs.
| Participants | Part B: VX-371 in HS + IVA | Part B: HS + IVA | Part B: VX-371 + IVA | Part B: Placebo + IVA |
|---|---|---|---|---|
| Participants with TEAEs | 5 | 17 | 5 | 9 |
| Participants with Serious TEAEs | 0 | 0 | 1 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
| Percentage of predicted FEV1 | Part A: VX-371 in HS | Part A: HS | Part A: VX-371 | Part A: Placebo |
|---|---|---|---|---|
| Part A: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | 0.989 ± 0.7097 | -0.531 ± 0.7202 | -0.491 ± 1.0736 | -1.329 ± 1.0730 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
| Percentage of predicted FEV1 | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|
| Part B: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | 4.721 ± 1.9314 | 1.722 ± 1.1976 | -0.592 ± 2.5011 | -0.965 ± 1.8388 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
| Percentage of predicted FEV1 | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|
| Part B: Absolute Change From Part B Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29 | 2.528 ± 1.8633 | 1.678 ± 1.1414 | -1.018 ± 2.3797 | -2.040 ± 1.7427 |
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
| score on a scale | Part A: VX-371 in HS | Part A: HS | Part A: VX-371 | Part A: Placebo |
|---|---|---|---|---|
| Part A: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29 | 4.23 ± 18.076 | 3.58 ± 16.715 | 0.98 ± 12.915 | 7.04 ± 16.728 |
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from study baseline \>0 indicated improvement. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
| score on a scale | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|
| Part B: Change From Study Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29 | 16.67 ± 14.487 | 1.39 ± 17.153 | 7.41 ± 3.208 | -5.56 ± 23.307 |
QOL- PCD adult version has following 10 domains: lower respiratory symptoms, emotional functioning, treatment burden, role, social functioning, vitality, health perception, upper respiratory symptoms, physical functioning and hearing symptoms. The total numbers of items in the lower respiratory symptoms domain are 6 in the questionnaire for adults. All items are scored using a 4-point Likert scale. Scaled score calculated as: \[Sum of scores - (n\*1)\] / \[(n\*4) - (n\*1)\]\*100. Where 'n' is the number of questions in domain. The total score range is from 0-100, where higher score indicates greater improvement. Change from Part B baseline \>0 indicated improvement. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
| score on a scale | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|
| Part B: Change From Part B Baseline in Quality of Life-Primary Ciliary Dyskinesia (QOL-PCD) (Adult Version) Lower Respiratory Symptoms Domain Score at Day 29 | 11.11 ± 15.713 | 1.39 ± 19.928 | 5.56 ± 16.667 | -7.41 ± 10.344 |
SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
| score on a scale | Part A: VX-371 in HS | Part A: HS | Part A: VX-371 | Part A: Placebo |
|---|---|---|---|---|
| Part A: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged Greater Than or Equals to (>=) 16 Years at Day 29 | -1.28 ± 8.452 | -2.17 ± 6.462 | 1.54 ± 8.576 | -1.52 ± 9.082 |
SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. The study baseline is defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug in the study.
| score on a scale | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|
| Part B: Change From Study Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29 | -1.69 ± 7.442 | -6.87 ± 6.571 | 0.78 ± 5.879 | 4.52 ± 16.995 |
SGRQ measured health-related quality of life among participants with respiratory diseases. It is a 40 items questionnaire grouped into three domains (Symptoms, Activity, and Impacts). Total scores range from 0 to 100. Higher score reflected worse quality of life. Part B baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of ivacaftor in Part B and after the last dose in Period 2.
| score on a scale | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|
| Part B: Change From Part B Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score for Participants Aged >=16 Years at Day 29 | -3.90 ± 4.331 | -2.64 ± 6.575 | 0.97 ± 7.561 | 3.19 ± 11.649 |
Collected over Part A: From first dose of study drug up to 84 days; Part B: Day 85 up to 28 days after last dose of study drug (56 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: VX-371 in HS | 0/81 (0%) | 1/81 (1.2%) | 40/81 (49.4%) |
| Part A: HS | 0/80 (0%) | 1/80 (1.3%) | 27/80 (33.8%) |
| Part A: VX-371 | 0/37 (0%) | 1/37 (2.7%) | 12/37 (32.4%) |
| Part A: Placebo | 0/36 (0%) | 1/36 (2.8%) | 16/36 (44.4%) |
| Part B: VX-371 in HS + Ivacaftor | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Part B: HS + Ivacaftor | 0/27 (0%) | 0/27 (0%) | 15/27 (55.6%) |
| Part B: VX-371 + Ivacaftor | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Part B: Placebo + Ivacaftor | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Event | Part A: VX-371 in HS | Part A: HS | Part A: VX-371 | Part A: Placebo | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 1/7 | 0/12 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/81 | 0/80 | 0/37 | 1/36 | 0/11 | 0/27 | 0/7 | 0/12 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 0/81 | 1/80 | 1/37 | 0/36 | 0/11 | 0/27 | 0/7 | 0/12 |
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 1/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 0/7 | 0/12 |
| Event | Part A: VX-371 in HS | Part A: HS | Part A: VX-371 | Part A: Placebo | Part B: VX-371 in HS + Ivacaftor | Part B: HS + Ivacaftor | Part B: VX-371 + Ivacaftor | Part B: Placebo + Ivacaftor |
|---|---|---|---|---|---|---|---|---|
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/81 | 3/80 | 3/37 | 0/36 | 0/11 | 2/27 | 2/7 | 1/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/81 | 8/80 | 4/37 | 3/36 | 3/11 | 2/27 | 0/7 | 1/12 |
| HeadacheNervous system disorders | 8/81 | 7/80 | 2/37 | 6/36 | 3/11 | 4/27 | 0/7 | 3/12 |
| DiarrhoeaGastrointestinal disorders | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 5/27 | 1/7 | 0/12 |
| FatigueGeneral disorders | 2/81 | 4/80 | 2/37 | 2/36 | 2/11 | 1/27 | 1/7 | 0/12 |
| Lipase increasedInvestigations | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 0/7 | 2/12 |
| Weight decreasedInvestigations | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 1/7 | 0/12 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 1/7 | 0/12 |
| Eye pruritusEye disorders | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 1/7 | 0/12 |
| Vision blurredEye disorders | 0/81 | 0/80 | 0/37 | 0/36 | 0/11 | 0/27 | 1/7 | 0/12 |
Part A Full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug in Part A and had a confirmed diagnosis of primary ciliary dyskinesia (PCD).
| Age, Continuous(years) | Part A: VX-371 in HS, Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Total |
|---|---|---|---|---|---|
| Mean | 29.19 ± 10.861 | 27.98 ± 13.104 | 27.62 ± 16.633 | 24.33 ± 12.866 | 27.80 ± 12.954 |
| Sex: Female, Male(Participants) | Part A: VX-371 in HS, Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Total |
|---|---|---|---|---|---|
| Female | 29 | 24 | 15 | 10 | 78 |
| Male | 14 | 17 | 6 | 8 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Part A: VX-371 in HS, Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 2 | 0 | 7 |
| Not Hispanic or Latino | 41 | 37 | 18 | 18 | 114 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Part A: VX-371 in HS, Then HS | Part A: HS, Then VX-371 in HS | Part A: VX-371, Then Placebo | Part A: Placebo, Then VX-371 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 3 | 1 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 1 | 5 |
| White | 39 | 36 | 17 | 14 | 106 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Nov 2018, 27 months.
Results were first posted in Dec 2021, 3 years after primary completion. A results delay was requested in Nov 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Idrevloride · Ivacaftor
Parion Sciences